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Background: Faecal Microbiota Transplant (FMT) has improved outcomes for the treatment of Clostridioides
difficile infection (CDI) compared to antibiotic therapy. FMT is classified as a medicinal product in the United
Kingdom, similar to the USA and Canada, limiting supply via stool banks without appropriate licencing. In
the largest UK cohort to date, we describe the clinical outcomes for 124 patients receiving FMT for recurrent
or refractory CDI and present a framework to produce FMT as a licenced medicinal product.
Methods: Anonymous unrelated healthy donors, screened via health assessment and microbiological testing
donated stool. In aerobic conditions FMT aliquots were prepared for immediate use or frozen storage, follow-
ing a production framework developed to comply with Good Manufacturing Practice. Outcome measures
were clinical response to FMT defined as resolution of diarrhoea within seven days and clinical cure defined
as response without diarrhoea recurrence at 90 days.
Findings: Clinical response was 83¢9% (95% CI 76¢0%90¢0%) after one treatment. Clinical cure was 78¢2% (95%
CI 67¢4%89¢0%) across the cohort. Refractory cases appeared to have a lower initial clinical response rate
compared to recurrent cases, however at day 90 there were no differences observed between these groups.
Interpretation: The methodology developed here enabled successful licencing of FMT by The Medicines and
Healthcare products Regulatory Agency as a medicinal product. This has widened the availability of FMT in
the National Health Service via a stool bank and can be applied in other centres across the world to improve
access to safe and quality assured treatments.
© 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)e).
pen access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
Clostridioides difficile infection (CDI) is the leading cause of antibi-
otic associated gastrointestinal disease causing significant morbidity
and mortality [1]. Clinical response to antibiotic treatment of CDI is
80% in the primary episode [2] and rapidly falls to only 3040% in
recurrent disease [3]. Faecal Microbiota Transplant (FMT) is highly
Research in context
Evidence before this study
FMT has been used mainly for the treatment of recurrent CDI.
Small numbers of refractory and severe cases have been success-
fully treated; however the data in this area is limited. Several dif-
ferent methodologies have been described for FMT production,
nonetheless generally comparable efficacy rates have been
reported across the literature. Most studies do not discuss
important aspects of processing pertaining to successful regula-
tion. Lack of guidance in this area can limit the establishment
and supply of FMT.
Added value of this study
The clinical cohort described in this study adds to the evidence of
FMT use in antibiotic refractory CDI cases. In addition the
detailed methodology and procedures presented provide a
proven framework for the production of FMT as a licenced
medicinal product to meet regulatory requirements.
Implications of all the available evidence
Combining the presented framework alongside published
guidelines and the existing clinical evidence base, will enable
the development of licenced FMT services, ensuring the clinical
governance of FMT supply. This will allow more equitable
access to treatment and support future research for other con-
ditions such as Inflammatory Bowel Disease, Graft versus Host
Disease and other non-gastrointestinal disorders associated
with gut microbiome disturbance.
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improved efficacy rates compared to antibiotic therapy [4,5]. It has
also been used for the treatment of severe CDI [6]. The National Insti-
tute for Healthcare and Excellence recommend FMT for the treatment
of recurrent CDI, in patients failing to respond to antibiotics and other
treatments [7].
Prior to 2015, it was believed that FMT would fall under the
Human Tissue (Quality and Safety for Human Application) Regula-
tions 2007 and be regulated by the Human Tissue Authority (HTA).
This perspective changed in England in 2015, when FMT was defined
as a medicinal product under The Human Medicines Regulations
2012 [8]. In the USA and Canada, FMT is considered a biologic drug,
while in Europe, without a formal position from the European Medi-
cines Agency, a mixture of regulatory frameworks exist [9]. As a
medicinal product under regulation by the Medicines and Healthcare
products Regulatory Agency (MHRA), FMT can be prescribed and pro-
duced locally by a medical practitioner for a named patient under a
pharmacy exemption. However production and supply to a third
party, via a stool bank, requires a Specials licence.
A UK survey showed that only 28% (36/130) of hospitals reported
using FMT for CDI. Barriers to uptake were a lack of facilities and
understanding of how to establish FMT services [10]. Both European
and UK FMT guidelines for good clinical practice and standardisation
have been published [1113], and there have been commentaries
describing the practical and logistical requirements for stool bank
operation [9,14], however there is little guidance regarding the spe-
cific methodology compliant with the production of a safe and quality
assured medicinal product.
We have worked with the HTA and then the MRHA to create a
licenced FMT service, using a banked supply of FMT for the treatmentof CDI within the National Health Service (NHS). We present outcome
data for the first 124 patients treated under HTA approval and pres-
ent the methodology framework which supported MHRA licencing.
Our licenced service is currently supplying FMT to the population of
England free of charge under an NHS innovation tariff. The produc-
tion framework presented will be of value to practitioners in other
countries wanting to establish a regulated service for the treatment
of CDI and other conditions.
2. Methods
2.1. Preparation of medicinal FMT
The core practical steps used to prepare FMT did not differ
between HTA approval and MHRA licencing. However to develop and
comply with Good Manufacturing Practice (GMP) required for MHRA
licencing, the FMT facility processes and policies were embedded
within a Quality Management System, overseen by a Qualified Person
and developed to meet the requirements outlined within The Orange
Guide [15]. A summary of key steps taken to comply with GMP are
presented in Table 1.
2.2. FMT donor selection and screening
Donors were healthy un-related anonymous volunteers, 18 and
<50 years of age, with a Body Mass Index 18¢5 and 25, who had
not received antibiotics in the preceding three months. Screening
was via health, social and travel questionnaire, clinical assessment
(undertaken by an independent clinician) and microbiological testing
(Table 2). Health, social and travel exclusion criteria are presented in
the supplementary information 1. FMT was quarantined until donor
screening results and all health questionnaires were completed (as
presented in Table 2) and written confirmation of donor eligibility
was received from the independent clinician.
2.3. FMT preparation
All FMT was prepared in a single centre in Birmingham and dis-
tributed to eleven NHS hospitals for administration. FMT processing
was under aerobic conditions in a containment level two laboratory,
within a sole use class two microbiological safety cabinet which was
decontaminated before and after use using chlorine dioxide-based
disinfectant (Tristel Solutions Ltd, UK) and ultra violet light (254 Nm,
30 min). Faeces were processed <6 hours post defecation, Bristol
Stool type 25, brown in colour and contained no macroscopic blood
or mucus. FMT material was prepared by combining 90 § 5 g of fae-
ces from a single donor with either 150 ml IV grade 0¢9% Saline (fresh
FMT) or 150 ml IV grade 0¢9% Saline containing 10% v/v glycerol (fro-
zen FMT) in a sterile Nasco Whirl-Pak filter bag (Labs UK Ltd, UK).
This was homogenised in a Mix-1 stomacher (AES Chemunex, France)
for two minutes (Fig. 1). The filtrate was either transferred to an
enteral feeding syringe and used immediately (fresh FMT) or stored
in BiotiteTM Containers (Alpha Laboratories, UK) in 60 ml aliquots at
80 °C for up to 24 weeks (frozen FMT). FMT reference samples from
every batch were retained and stored at 80 °C.
2.4. Use of medicinal FMT in the clinical cohort
Patients receiving FMT were treated as they presented to health-
care, as part of routine management of CDI. The cases reported here
therefore represent real world consecutive eligible patients offered
FMT within the standard care pathway. From March 2013 until Octo-
ber 2014, 31 patients were treated with fresh FMT. From November
2014 to September 2016, 93 patients were treated with frozen FMT.
Table 1
Procedures and control measures taken to ensure compliance with the Orange Guide and MHRA licencing.
FMT production facility FMT donor screening FMT preparation FMT supply
Product quality
assurance
Dedicated manufacturing facility
Equipment IQ/PQ/OQ1
Environment and equipment
temperature monitoring
Equipment calibration, mainte-
nance and verification
Prospective equipment perfor-
mance monitoring
Controlled facility access
Integration into a Quality
Management System
Standardised donor screening
UKAS (or equivalent) accredited
microbiological testing
Independent clinical assessment
of donors
Regular review of donor
screening policy
Use of written document
controlled SOPs
Defined donation acceptance
criteria (based on visual,
consistency and storage time
criteria)
Consumable supplier validation
to establish suitability of
consumables
Use of written document
controlled SOPs
Batch release from quarantine
by Qualified Person
Standardised training and
competency assessment of
personnel
FMT Reference sample storage
Validation of transport procedures
to maintain appropriate storage
conditions during transport
Detailed instruction for storage
and use, with specified expiry
date
Thawing and re-freezing
prohibited
Competent transport couriers
Cross contamination
minimisation
Validation of cleaning
methodology
Environmental monitoring for
enteric indicator organisms,
with comparison to Grade D
clean room recommended
limits
Exclusion of materials from the
facility which can support
microbial growth
Standard collection protocol
utilising sterile containers
Specified expiry timescales for
storage
Single batch production2
Single use consumables and
excipients
Closed filtering and homogeni-
sation
Operator personal protective
equipment (laboratory coat,
gloves, hair net, mask and
overshoes)
Production within a Class 2
microbiological safety cabinet
Direct transfer of filtrate from
sterile filer bag into primary
container
Packaging compliant with P650
packing Instruction for biological
specimens
Traceability Use of electronic specimen
tracking system for donations,
batches, lots and reference
samples within the FMT
facility
Unique anonymous Donor
Identifiers
Batch processing records3
Unique and traceable batch
and lot numbering
Supply on named patient basis
only
Standardised electronic requesting
Validation certificate supplied
with every FMT for retention in
the patients notes4
Product labelling compliant with
British Pharmacopoeia 2017
general monograph for
unlicensed medicines
1 IQ/PQ/OQ: installation qualification, performance qualification, operating qualification.
2 Batch of FMT defined as all lots prepared from a single faeces donation from an individual donor.
3 Batch processing records recorded date and time of stool production, unique donor identification number, donation macroscopic appearance, consumable and excipient lot num-
bers and expiry dates, weight of donor stool used, volume of saline used, volume of glycerol used, date and time of production, unique batch and lot numbers and operator name.
4 The validation certificate documents unique treatment identification numbers, source of FMT and production location, storage instructions, and statement confirming donor
screening testing acceptability.
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bridgeshire and Yorkshire) were supplied with FMT from the Bir-
mingham central stool bank.
2.5. Patient inclusion and exclusion criteria
Patients treated with FMT were >18 years of age, clinically symp-
tomatic with diarrhoea (defined as having as 3 type 6/7 stools per
day for two consecutive days [16]) and were microbiologically con-
firmed active cases (defined as C. difficile glutamate dehydrogenase
positive and either stool toxin positive by Enzyme Immunoassay
(EIA) or C. difficile toxin gene positive by PCR assay within four weeks
prior to treatment). Two groups of CDI cases were treated, recurrent
CDI (defined as 3 episodes of CDI) and CDI refractory to antibiotic
treatment (defined as continuing diarrhoea despite antibiotic treat-
ment). FMT was offered for refractory CDI  seven days after the start
of the second antibiotic treatment course. Absolute patient exclusion
criteria were decompensated liver cirrhosis and significant food
allergy. Named patient FMT requests were approved internally by a
clinician, via assessment of the clinical information supplied on a
standard request form (supplementary material 2) and against the
treatment definitions defined above. Informed patient consent wassought prior to FMT treatment according to local hospital policy and
a pre-FMT patient serum was stored.2.6. FMT administration
Prior to FMT all cases were treated with vancomycin, metronida-
zole or fidaxomicin (varying courses and lengths), which was stopped
12 hours prior to FMT treatment. FMT was predominantly adminis-
tered via nasogastric (NG) tube, adapted from previously reported
protocols [17] and following a standard protocol distributed to hospi-
tals by the Birmingham stool bank (supplementary material 3).2.7. Follow up and outcomes
Patients were followed up from clinical records, laboratory data
and, when necessary, by telephone questionnaire to the physician or
patient, using a structured pro-forma distributed to all centres. Out-
come measures were, clinical response to FMT defined as resolution
of diarrhoea within seven days and clinical cure defined as response
without diarrhoea recurrence at 90 days. Total follow up time for
each case was 90 days.
Table 2
Screening protocol for FMT donors.
Screening method Frequency
Fresh FMT Frozen FMT (MHRA licenced
protocol)
Health screening question-
naire 1
3 monthly 7 days prior to every
10 day donation period
Health screening question-
naire 2
Day of donation Final day of donation (day
10)
Microbiological testing of
blood
3 monthly 7 days prior to every
10 day donation period
HIVa (4th generation
immunoassay)
Hepatitis B Virus (HBsAGb and
anti HBcc immunoassay)
Hepatitis C Virus (anti-HCVd
immunoassay)
Syphilis (total antibody
immunoassay)
Hepatitis A Virus
(IgM immunoassay)
Hepatitis E Virus
(IgM immunoassay)
HTLVe 1 and 2
(IgG immunoassay)j
Microbiological testing of
faeces
3 monthly 7 days prior to every
10 day donation period
lSelected tests repeated on
donation day 5 and
day 10.
Clostridioides difficile
(culture and PCRf)l
Norovirus (PCR)l
Salmonella species (culture)l
Shigella species (culture)l
Escherichia coli O157 (culture)l
Thermophilic Campylobacter
species (culture)l
Giardia antigen (EIAg)
Cryptosporidium antigen (EIA)
Helicobacter pylori stool
antigen (EIA)k
ESBLh producing Enterobacter-
iaceae (Enrichment culture)
CPEi (Selective Chromogenic
Culture)
Ova, cysts and parasites
(microscopy)m
The donor screening protocol was adapted from the American Gastroenterological
Association guidelines for donor screening (Bakken et al 2011)[18] and Annex B of the
HTA Guide to Quality and Safety Assurance of Human Tissues and Cells for Patient
Treatments. All microbiological tests were performed by a UKAS accredited microbiol-
ogy laboratory.
a Human Immunodeficiency Virus.
b Hepatitis B surface antigen.
c Hepatitis B core antibody.
d Hepatitis C antibodies.
e Human T-cell lymphotropic Virus.
f Polymerase Chain Reaction.
g Enzyme Immunoassay.
h Extended spectrum b-lactamase.
i Carbapenemase producing Enterobacteriaceae.
j Subject to risk assessment.
k Screening methodology for H. pylori was modified during the study period from
IgG serological testing to stool antigen testing.
l Day 5 and day 10 stool testing samples were pooled aliquots of donations 15
and donations 610 respectively.
m Observation of any ova, cysts or parasite structures results in donor exclusion.
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Univariate analysis was conducted using the t test for continuous
variables and Fisher’s test for binary variables. Multivariate analysis
was performed using multiple logistic regression analysis. Data were
analysed using Stata Statistical Software (Release 15. College Station,
TX: StataCorp LLC).2.9. Ethics
The local research ethics committee reviewed the study plan
before data collection and concluded that full ethical approval was
not required on the basis that this study was an anonymised retro-
spective audit of outcomes from routine clinical care.3. Results
3.1. Clinical outcomes
A total of 124 patients (median age 78¢5 years) received FMT
treatment (Fig. 2), 63% (78/124) of the cohort were female. The
majority of patients received FMT via nasogastric tube, alternative
routes of administration included colonoscopy (n = 1), PEG (n = 3)
and gastroscopy (n = 1). There were 71 and 53 cases of recurrence
CDI and refractory CDI respectively. Over half of the cases (75/124)
were microbiologically confirmed stool toxin positive by EIA, with
the remainder stool toxin negative by EIA, but toxin gene positive by
PCR. Patient demographics are presented in Table 3. Six patients
received a second FMT due to disease recurrence, between 12 and
106 days. Clinical response to a single FMT in 118 eligible cases
(Fig. 2) was 83.9% (95% CI 76¢0%90¢0%) and found to be higher for
those treated in the recurrence group compared to the refractory
group (91¢0% vs. 73¢0%, p = 0¢007) and in those with an increased
number of CDI episodes (OR 1¢8, p = 0¢006). Cases were more likely to
be alive at day 90 if they had shown clinical response to FMT at day 7
compared to non-responders (p = 0.05). No significant difference was
observed in clinical response when comparing age, gender, FMT
preparation (fresh vs. frozen) or CDI microbiology testing result, by
multivariate analysis (Table 4).
Response without recurrence of disease was observed in 78¢2%
(95% CI 67¢4%89¢0%) of those alive at day 90. At day 90 no difference
in response without recurrence was observed between groups.3.2. Adverse events and side effects
All solicited adverse events were investigated with root cause
analysis and reported to the HTA/MHRA. Two patients died
within 7 days of FMT treatment. The first died two days after
FMT from perforated viscus and presumed uncontrolled CDI
despite FMT (as assessed by a senior clinician). The second died
four days post FMT from underlying bowel cancer. There were
two cases of bacteraemia post FMT, both receiving fresh FMT. The
first case developed fever 3 hours post FMT, blood cultures grew
Escherichia coli and urine analysis from a sample taken on the
day of FMT demonstrated a pyuria (1078 WBC/ml) with a scanty
growth of bacteria which were not identified. Twenty four hours
post FMT the second case was noted to have hypoactive delirium
and a rising CRP (increasing to 200), blood cultures were taken
and grew Serratia marcescens. The patient remained afebrile and
had a normal peripheral white blood cell count. The patient’s
long term urinary catheter had been replaced on the day of FMT
treatment. Urine taken at the time of re-catheterised also grew S.
marcescens, with the same antibiogram as the blood culture iso-
late. Reference FMT samples for the second case were investi-
gated by selective direct and enrichment culture and S.
marcescens was not isolated from FMT reference samples. Both
cases responded to systemic antibiotic treatment for the acute
clinical deterioration.
Minor adverse events reported were constipation (n = 4), bloating
(n = 1), flatulence (n = 1), gagging on NG tube (n = 1) and abdominal
pain (n = 2).
Fig. 1. FMT production in the licenced production facility. (a) weighing out donor faeces into a Nasco-whirl pak filter bag in a class 2 microbiological safety cabinet. (b) homogenisa-
tion of stool using a stomacher. (c) aliquoting of prepared FMT into containers for storage. (d) final packaging and labelling of frozen FMT.
132 paents 
consented for FMT
124 administered FMT 
treatments
99 paents with clinical 
response at day 7 post 
FMT
6 non-evaluable paents
Lost to follow up (n=3)
Dieda (n=2)
Received fidaxomicin      
concurrently with FMT (n=1)
8 FMTs not administered
NG pulled out (n=5)
Paent refusal post consent       
(n=3)
118 evaluable paents 
at day 7 post FMT
19 failed to respond at day 7 
post FMT
78 paents alive at day 
90
21 paents died before day 
90
61 paents 
experienced response 
without recurrence of 
diarrhoea at day 90
17 paents suffered from 
recurrence of diarrhoea by 
day 90b
Fig. 2. Number of patients receiving FMT and outcomes.
aOne patient died two days post FMT, with perforated viscus and CDI. Second
patient died four days post FMT, from bowel cancer.
bSix patients were re-treated with a second FMT, of whom four clinically
responded to FMT by day 7 and two of these patients demonstrated clinical response
without recurrence of disease at day 90.
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This is the largest UK series presenting FMT outcome data for the
treatment of CDI and the first of methodology which meets the
requirements of a MHRA specials licence. In our uncontrolled retro-
spective case series, we found using a single FMT protocol clinical
response at day 7 (83¢9% [95% CI 76¢0%90¢0%]) and response with-
out recurrence at 90 days (78¢2% [95% CI 67¢4%89¢0%]) was broadly
similar to that observed previously [4,19,20]. Administration in our
cohort was predominantly via the upper gastrointestinal (GI) route,
however one patient received FMT by colonoscopy. A specific
administration procedure was available to clinicians, but protocol
deviation may have occurred in this real world setting, possibly
introducing centre specific bias. Meta-analysis comparing FMT
administration routes, have observed a trend toward higher efficacy
rates with lower GI compared to upper GI administration, but this
often does not reach statistical significance [19,20]. The low num-
bers of lower GI administration precluded analysis here. This series
included both fresh FMT and frozen FMT, reflecting the develop-
ment of the service over time. Similarly to that previously reported
[19,21], we observed no significant difference in FMT outcome
between these groups, although the study was not powered to
assess such differences and fresh FMT comprised only 25% of cases
(31/124). Frozen supply was found to be advantageous over fresh
FMT on the basis of logistics, turnaround time and minimising the
donor screening window, factors which have also been highlighted
by others [9,21].
The indication for FMT was recurrent CDI in 57% of cases; the
remainder were defined as refractory cases. While other studies have
included refractory cases [2123], the overall numbers are small and
this report presents one of the largest refractory case series to date,
particularly in the primary and secondary episode of infection. The
use of FMT in refractory CDI is complicated by the absence of
accepted standard definitions. In some published studies recurrent
and refractory are used interchangeably or poorly defined [22,24,25].
It has been defined as CDI not responding to conventional therapy
without specific symptom duration thresholds [26]. Others have
defined it as ongoing diarrhoea despite at least five days of oral van-
comycin 125 mg given six hourly [27]. In this series the clinical
response to FMT, measured at day seven, was higher in recurrent CDI
compared to refractory cases (91¢0% vs. 73¢0%, p = 0¢007), however at
day 90 no difference was observed in outcome between these groups.
A recent meta-analysis found lower cure rates in studies which
included both recurrent and refractory patients, compared to studies
including only recurrent cases (weighted pooled rate 63.9% vs. 79%;
P< .001)(19). Due to the use of FMT in this series within routine clini-
cal care, patients were pre-treated with variable CDI antibiotic course
lengths. This uncontrolled variable could have introduced bias in our
results, particularly for biased the seven day outcome measure across
both refractory and recurrence groups. In addition the retrospective
design of our study will limit the strength of conclusions that can be
Table 3
Demographics and clinical features of study population.
Fresh FMT (n = 31) Frozen FMT (n = 93) Total (n = 124)
Sex Male 17 (37%) 29 (63%) 46 (37%)
Female 14 (18%) 64 (82%) 78 (63%)
Age Median (range) 81 (4493) 76.5 (2299) 78 (1999)
Indication Recurrent CDI 14 (20%) 57 (80%) 71 (57%)
Mean prior CDI episodes (range) 3.0 (34) 4.0 (38) 3.8 (38)
Refractory CDI 17 (32%) 36 (68%) 53 (43%)
Mean prior CDI episodes (range) 1.1 (12) 1.3 (12) 1.2 (12)
Clostridioides difficile testing result C. difficile stool toxin positive by enzyme immunoassay 21 (28%) 54 (72%) 75 (60%)
C. difficile stool toxin negative by enzyme immunoassay andstool toxin
gene positive by polymerase chain reaction assay
10 (20%) 39 (80%) 49 (40%)
6 V.L. McCune et al. / EClinicalMedicine 20 (2020) 100301drawn from this finding. Time to resolution of diarrhoea was mea-
sured in this study, although not available for all patients, and was
not found to be different between recurrence and refractory groups.
FMT re-treatment was not applied universally to non-responders
here. It has been shown that re-treatment with a second FMT
increases clinical response rate [19], particularly in complicated or
refractory cases [28].
Only microbiologically confirmed and clinically symptomatic
patients were offered FMT, this approach aimed to avoid using FMT
in asymptomatic C. difficile carriers. Those who were negative for C.
difficile toxin in stool by EIA but positive for toxigenic C. difficile by
PCR may have been more likely to have alternative reasons for ongo-
ing diarrhoea, which could have limited our findings; however these
patients were being treated clinically as CDI cases at the time of
request for FMT. By definition the refractory group had failed to
respond to antibiotics for CDI, which may increase the possibility of
other contributing causes of diarrhoea in these cases, particularly as
the incidence of resistance to vancomycin and fidaxomicin in C. diffi-
cile is thought to be low.
Under MHRA regulation in England FMT stool banks are now
required to satisfy detailed manufacture requirements which adds
complexity and cost of production. Within a Specials licence FMT can
only be released for use by the Qualified Person when specified donor
screening, production and storage criteria are satisfied. Integration of
the service into a Quality Management System (QMS) is critical to suc-
cessful operation of a licenced FMT facility. The QMS ensures that core
components of the service are delivered consistently with appropriate
quality assurance activity. It necessitates audit, risk management, thor-
ough facilities management, quality improvement via the investigation
of non-conformance, training and competence assessment of person-
nel, and document control. The minimisation of microbial contamina-
tion is a key component of GMP compliant FMT production. We have
developed a closed fully disposable system for the preparation of FMT
in a class two microbiological safety whichminimises the risk of exter-
nal microbial contamination. Other published methodologies have
used external filtering systems and blenders, which may fail toTable 4
Comparison of outcome measures across the cohort by multivariate analysis.
Clinical resp
Responder Non-resp
Recipient gender
Female 64 (84%) 12 (16%)
Male 35 (83%) 7 (17%)
Stool characteristics
Fresh 25 (81%) 6 (19%)
Frozen 74 (85%) 13 (15%)
FMT indication
Recurrence 64 (91%) 6 (9%)
Refractory 35 (73%) 13 (27%)
C. difficile testing result
C. difficile stool toxin EIA positive 60 (83%) 12 (17%)
C. difficile stool toxin EIA negative, stool toxin PCR positive 39 (85%) 7 (15%)minimise the risk of potential contamination [11,14]. Further to this
FMT production is conducted in a dedicated clean non-sterile
manufacturing room, which environmental monitoring has shown
complies with grade D clean room recommended limits. This level of
environmental review has not previously been commented on in
international guidelines and is an evolving area for consideration. Con-
trol measures utilised to minimise the environmental contamination
of the production facility are validated decontamination protocols,
physical barriers (Tack-mats), limited personal access, the use of per-
sonal protective equipment (laboratory coats, hair nets and over-
shoes), and limiting material in the facility which supports microbial
growth. The aim of the above GMP processes is to standardise and
maintain the quality of FMT production as far as practically possible.
However, the inherent variability in composition of human faeces
between donors and within the same donor over time prevents true
consistency and reproducibility control across FMT batches, as would
be expected for the production of a drug-based medicinal product. In
addition there is currently an absence of accepted profiling standards
to quality assure donated faeces. Although it has been shown that
higher bacterial diversity in donor faeces is associated with improved
FMT clinical outcomes, the precise mechanisms of action of FMT are
not fully understood, which limits the adoption of quality assurance
testing during production. The selection of infectious agents screened
for during FMT donor assessment varies between institutions [29] and
until recently has not been expressly specified by regulating agencies,
particularly those regulating FMT as a biological drug. However, a gen-
eral consensus is emerging with the publication of guidelines for FMT
production and use [11,12]. These guidelines recommend screening
for multidrug resistant organisms (MDRO), in particular those produc-
ing Extended Spectrum b-lactamases (ESBL) and Carbapenemase pro-
ducing Enterobacteriaceae (CPE), although other centre’s protocols do
not always specify MDRO screening [29]. This topic has become rele-
vant with the recent Food and Drug Administration (FDA) safety alert
reporting two immunocompromised patients transplanted from the
same donor who became colonised from the FMT with ESBL producing
E. coli, with the death of one patient [30]. The FDA has mandated allonse at day 7 Clinical cure at day 90
onder Total p value Responder Non-responder Total p value
0¢9 0.32
76 43 (81%) 10 (19%) 53
42 23 (72%) 9 (28%) 32
0¢57 0¢36
31 21 (84%) 4 (16%) 25
87 45 (75%) 15 (25% 60
0¢007 0.4
48 38 (75%) 13 (25%) 51
70 28 (82%) 6 (18%) 34
0¢835 0.26
72 44 (81%) 19 (19%) 54
46 22 (71%) 9 (29%) 31
V.L. McCune et al. / EClinicalMedicine 20 (2020) 100301 7holders of Investigational New Drug applications for FMT to not
only test for ESBL and CPE, but also methicillin resistant Staphylo-
coccus aureus (MRSA) and vancomycin resistant Enterococci (VRE).
The diagnostic methods used to screen for MDROs and other
pathogens should be validated and demonstrate acceptable sensi-
tivity and specificity, to ensure the accuracy of donor testing.
Although many guidelines specify the pathogens to screen for
during donor selection, they often do not address which testing
methodology to use. To maintain the quality of results, donor
testing should be undertaken by accredited diagnostic laborato-
ries following standard methods, such as those described in the
UK Standards for Microbiological Investigation. In our own ser-
vice, the donor screening algorithm continues to develop dynami-
cally. For example to improve the diagnostic sensitivity of testing
for enteric pathogens, culture methods will be replaced with
Polymerase Chain Reaction (PCR) based tests. This will also enable
the detection of pathogens not previously screened for such as
all Shiga toxin producing E. coli (STEC) and rotavirus. The reper-
toire of screening tests for FMT to be given to immunocompro-
mised patients has been discussed [9,12]. The groups concluded
that caution should be exercised and the use of Cytomegalovirus
(CMV) and Epstein-Barr Virus (EBV) negative donors should be
considered for seronegative recipients, the role of other potential
pathogens being considered on a case by case basis. This is an
evolving area with a need for research, particularly with the
potential use of FMT in patients post bone marrow transplanta-
tion.
Prior to the re-classification of FMT as a medicine in the UK,
stool banks were being developed to widen FMT supply locally
and regionally [31,32]. Since the introduction of the revised regu-
latory position, FMT availability has been limited to intra-institu-
tion supply only. The systems described here now enable frozen
FMT supply across institutions within a Specials licence, the first
service of its kind in the UK. It is notable that encapsulation
methods had been described for FMT administration and shown
to be non-inferior to liquid FMT delivered via colonoscopy for the
treatment of recurrent CDI [33]. The procedures and control
measures that have been described here could be applicable to
FMT banks preparing liquid or encapsulated FMT to medical
product standards in other parts of the world.
Access to pre-screened FMT via larger centres is desired by clini-
cians in the UK, particularly as many perceive that lack of facilities
restrict local production [10]. A move towards FMT stool banks,
where FMT is produced to GMP standards under a Specials licence
will reduce costs through economy of scale and promote standardisa-
tion, safety and quality [9,11]. This approach will also widen access of
treatment and reduce inequity of access in the NHS. However, to
ensure the resilience of FMT services in the NHS steps need to be
taken to develop a networked hub and spoke model of supply under
appropriate licencing. Careful management of such a network would
enable efficient use of resources across the NHS, while maintaining
flexible and adaptable access to this life saving treatment. This will
require further engagement with the MHRA to develop this unique
regulatory framework appropriately.
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